OCUL

Ocular Therapeutix, Inc. (OCUL) Scenario Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Balance Sheet

Very strong liquidity with a current ratio of 13.1x and cash ratio of 12.2x.

Low leverage with debt-to-equity of 0.15x and debt-to-assets of 0.12x.

Net debt remains manageable relative to EBITDA despite negative operating earnings.

Profitability

Gross margin is high at 87.1%, showing strong product-level economics.

Operating and net margins remain deeply negative at -6.0% and -5.8%, respectively.

Returns are still poor, with ROE at -59.9% and ROIC at -50.2%.

Cash Flow

Free cash flow remains negative, with FCF yield at -11.5% and FCF-to-EBITDA still negative.

Operating cash flow is negative, indicating the core business is not yet self-funding.

Income quality is reasonable at 0.79, suggesting reported earnings are not overly distorted.

Valuation

Valuation remains rich at 32.8x EV/sales and 42.8x price/sales.

Negative earnings and cash flow make traditional earnings and FCF multiples less meaningful.

The balance sheet provides some support, but the stock still prices in substantial future improvement.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ocular Therapeutix, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →